U.S. Building Stock News

Why Sinclair Is On Investors’ Radar Right Now Sinclair (SBGI) has drawn attention after recent share price moves, with the stock around $16.34 and showing double digit returns over the past month and past three months, prompting fresh interest in its current valuation. See our latest analysis for Sinclair. The recent momentum, with a 7 day share price return of 11.92% and 30 day share price return of 12.61% at a current share price of $16.34, sits alongside a 1 year total shareholder return...

O’Reilly Automotive has already outlined plans in its 2025 Form 10-K to open 225 to 235 new stores in 2026, while integrating its 2024 acquisition of Groupe Del Vasto and expanding its dual DIY and professional automotive parts offering across North America. Recent commentary highlights that, even as inflation and tariffs pressure the do-it-yourself segment, O’Reilly’s professional business and distribution network are supporting ongoing expansion and attracting renewed attention from...

Hyatt Hotels (H) is back on investors’ radar after recent share price moves, with the stock showing mixed short term performance and a stronger picture over the past year and multi year periods. See our latest analysis for Hyatt Hotels. The latest 5.7% one day share price decline to US$161.50 comes after a period of steadier gains, with a 1 year total shareholder return of 15.8% and 5 year total shareholder return of 86.9%. This suggests longer term momentum remains intact despite short term...

Schlage, part of Allegion, has launched the Aspect Collection of interior door hardware, focused on bold design and easier installation. The collection expands Allegion's design centric portfolio and targets homeowners and professionals looking for more modern style options. The announcement highlights Allegion's emphasis on combining aesthetics with everyday usability in its residential product lineup. For investors watching Allegion (NYSE:ALLE), the Aspect Collection lands at a time when...

Bastion Asset Management has opened a significant new equity position in Parsons (NYSE:PSN). The holding ranks as a substantial position within Bastion’s portfolio. The move adds a new institutional holder to Parsons, which focuses on government and critical infrastructure projects. Parsons, traded on the NYSE under the ticker PSN, works across defense, intelligence, and critical infrastructure, areas that often rely on long term federal and public sector contracts. For investors watching...

Covista Inc., formerly Adtalem Global Education Inc., has completed a full corporate rebrand and name change. The company has also updated its ticker symbol to NYSE:CVSA. Alongside the rebrand, Covista introduced a three year growth plan targeting the U.S. healthcare workforce shortage. Covista operates in healthcare education, a segment that sits at the center of ongoing shortages across many clinical roles in the U.S. The company is presenting its new identity and plan as a response to...

Rubrik (NYSE:RBRK) is drawing fresh attention as recent updates highlight strong revenue gains, high net retention, and solid margins. The company reports operating with a very low share of its target market, which points to meaningful room for further enterprise cybersecurity adoption. Management continues to emphasize Rubrik’s subscription-based model and high switching costs as key supports for its position in data security. At a share price of $51.96, NYSE:RBRK sits against a backdrop...

Lennox International recently reported its fourth-quarter 2025 results, with both earnings per share and revenue coming in below analyst forecasts, while director Shane D. Wall sold 100 shares of common stock on February 25, 2026. This combination of an earnings shortfall and insider selling has sharpened investor focus on how resilient Lennox’s longer-term HVAC growth story may be. We’ll now examine how the weaker-than-expected quarterly earnings could influence Lennox’s previously outlined...

SkyWater Technology, Inc. reported past fourth-quarter 2025 sales of US$171.04 million versus US$75.49 million a year earlier, with a quarterly net loss of US$7.78 million, while full-year 2025 sales reached US$442.14 million and net income was US$118.92 million, reversing the prior year’s loss. Alongside these results, the company is sharpening its focus on growth and customer acquisition, appointing veteran semiconductor executive Christine Dunbar to lead sales and solutions engineering as...

Sysco has launched a new pilot program, Home Grown by Sysco, to expand locally sourced food offerings across select regions in North America. The company has also signed a nationwide distribution partnership with Reborn Coffee to support the coffee brand's franchise expansion across the United States. For investors watching NYSE:SYY, these moves come as Sysco trades around $91.16 per share, with returns of 25.5% year to date and 23.8% over the past year. The stock has also returned 29.6%...

If you are wondering whether Upwork's recent share price swings have created an opportunity or a value trap, looking closely at what the market is actually pricing in can help frame your next move. Upwork's shares last closed at US$13.42, with a 7 day return of 7.3%, a 30 day return of a 33.0% decline, a year to date return of a 32.4% decline, a 1 year return of an 8.8% decline, a 3 year return of 12.5% and a 5 year return of a 68.2% decline. Recent attention on Upwork has centered on how...

If you are wondering whether Day One Biopharmaceuticals' current share price lines up with its underlying worth, you are not alone. The stock most recently closed at US$10.60, with a 7 day return of 10% decline, a 30 day return of 5% decline, gains of 19.8% year to date and 17% over the past year, while the 3 year return sits at 43.4% decline. Recent news around Day One has largely focused on its development stage oncology pipeline and ongoing progress in clinical programs, which can...

What the latest earnings tell you about Diversified Healthcare Trust Diversified Healthcare Trust (DHC) has just reported fourth quarter and full year 2025 results, showing lower quarterly sales but a narrower net loss, a combination that naturally puts the stock back on investors’ radar. See our latest analysis for Diversified Healthcare Trust. That earnings update landed after a strong run in the shares, with a 90 day share price return of 39.96% and a year to date share price return of...

MannKind (MNKD) is back in focus after partner United Therapeutics introduced a soft mist inhaler designed to compete with Tyvaso DPI, raising fresh questions around MannKind’s future royalty stream and overall risk profile. See our latest analysis for MannKind. The stock’s 7 day share price return of 40.79% and 30 day share price return of 43.25% follow earnings that paired higher revenue with a quarterly loss, while the United Therapeutics soft mist inhaler news sharply reset sentiment...

In late February 2026, Pinnacle Financial Partners was highlighted by hedge funds as one of the ten leading banking stocks, with analysts citing stronger capital levels and higher earnings forecasts following its fourth-quarter results and management’s confident outlook. A few days later, hotter-than-expected inflation data and rising worries about credit risk in areas like private credit and leveraged loans led investors to reassess regional banks’ risk profiles, putting pressure on...

If you are wondering whether Kaiser Aluminum's current share price lines up with its underlying worth, this article walks through the key signals you will want to weigh. The stock last closed at US$130.14, with returns of 0.9% over 7 days, 6.1% over 30 days, 8.2% year to date, 90.5% over 1 year, 74.0% over 3 years, and 36.6% over 5 years. This performance sets an important backdrop for any value check. Recent coverage around Kaiser Aluminum has focused on how investors view its role within...

If you are looking at Acadia Realty Trust and wondering whether the current share price gives you good value, this article will walk through what the numbers are actually saying. The stock last closed at US$20.92, with returns of 3.2% over 7 days, 4.5% over 30 days, 1.4% year to date, a 5.6% decline over 1 year, 62.7% over 3 years and 30.0% over 5 years. Together, these figures provide a wide mix of recent and longer term outcomes to think about. Recent moves in Acadia Realty Trust's share...

Perimeter Solutions (NYSE:PRM) is dealing with operational and safety issues at its Sauget P2S5 facility that have led to reduced production and ongoing litigation as it seeks to take control of the site. The company has recently closed a sizeable acquisition while shifting more of its portfolio toward fixed and recurring contracts to support more consistent earnings. These developments affect a key production asset and the structure of Perimeter Solutions' revenue, with potential...

In recent weeks, UGI Utilities has begun additional natural gas system upgrades in Lancaster and implemented higher purchased gas cost rates, while its proposal for a US$99.40 million annual distribution rate increase has been temporarily suspended by the Pennsylvania Public Utility Commission for further review. Together, these infrastructure investments, customer bill impacts, and regulatory oversight highlight how UGI’s earnings profile is closely tied to state-level rate decisions and...

IDACORP, Inc. recently reported its full-year 2025 results, with sales of US$1.81 billion, revenue of US$1.81 billion, and net income rising to US$323.47 million, alongside higher basic and diluted earnings per share from continuing operations compared with 2024. At the same time, the company issued 2026 earnings guidance of US$6.25 to US$6.45 per diluted share, highlighting management’s expectations while signaling limited use of additional tax credits under Idaho’s regulatory...

Regeneron Pharmaceuticals (NasdaqGS:REGN) received FDA approval for Dupixent as the first treatment for allergic fungal rhinosinusitis, a chronic nasal disease. The FDA also accepted garetosmab for Priority Review for treating fibrodysplasia ossificans progressiva, a rare and serious genetic disorder. For you as an investor, these decisions highlight where Regeneron focuses its efforts: targeted biologic therapies in areas with limited existing options. Dupixent already sits at the center...

If you are wondering whether Altria Group's share price still lines up with its underlying value, this article walks through the key numbers that matter before you make any big calls. Altria Group recently closed at US$69.04, with returns of 2.2% over 7 days, 11.4% over 30 days, 20.5% year to date, 32.5% over 1 year, 88.4% over 3 years and 125.9% over 5 years. These figures raise fair questions about how the current price compares to estimated fair value. Recent news coverage has focused on...

If you are wondering whether Rayonier's current share price reflects its underlying value, this article will walk through what the numbers are actually saying. At a last close of US$21.49, Rayonier's shareholders have seen a 5.2% decline over the past week and a 5.5% decline over 30 days. The stock is also lower over 1 year, 3 years, and 5 years. These recent returns have put more attention on how Rayonier is being valued and what expectations are built into the current price. With the share...

If you are wondering whether Newmark Group's share price reflects its underlying worth today, you are not alone. This article is set up to help you frame that question clearly. The stock recently closed at US$14.52, with returns of a 3.8% decline over 7 days, 18.6% decline over 30 days, 14.4% decline year to date and 0.2% decline over the past year, while the 3 year and 5 year returns sit at 89.2% and 50.1% respectively. These moves have put valuation back in focus for Newmark Group...